Brahm Segal

Chair

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Evidence has shown that T-cell receptors (TCRs) that recognize the same epitopes may not be the exact TCR clonotypes but have slightly different TCR sequences. However, the changes in the genomic and transcriptomic signatures of these highly homologous T cells during immunotherapy remain unknown. Here, we examined the evolutionary features in circulating TCR clonotypes observed in tumors (tumor-infiltrating lymphocyte (TIL)-TCRs) by combining single-cell RNA/TCR sequencing of longitudinal blood samples and TCR sequencing of tumor tissue from a patient treated with anti-cytotoxic T-lymphocyte-associated protein 4/programmed cell death protein-1 therapy. We found frequent circulating CD8 + TIL-TCRs with identical complementarity determining region 3 (CDR3)α amino acid sequences but quasi-identical CDR3β and TCR α/β (TRA/TRB) sequences. Despite their sequence similarities, these highly homologous TIL-TCRs responded differently to immunotherapy, and exhibited distinct transcriptional signatures that were uniquely distinguished by the expression of GZMK . Overall, the expression of IFNG in CD8 + T-cell subsets including highly homologous TIL-TCRs increased when the patient achieved a response, but gradually decreased as the patient developed acquired resistance. Our findings provide insight into the cross-talk between T cells in the tumor microenvironment and those in the blood, and highlight that CD8 + T cells with highly homologous TCR sequences might display divergent transcriptional states and kinetics in response to immunotherapy.

Year:

2025

Impact of steroids on CD8 + T-cell differentiation and predictive value of the CX3CR1 score in patients with NSCLC treated with ICI therapy. A, Violin plot with median (red solid line) and the top and bottom quartiles (red dotted line) showing the frequency of PB CX3CR1 + CD8 + T cells in patients who were or were not on steroids at baseline. P value was calculated by a two-tailed Mann–Whitney U test. B, ORR for patients who were or were not on steroids at baseline and the maximal percent change of the CX3CR1 + subset among PB CD8 + T cells from baseline (CX3CR1 score) at 9 weeks. The ORR was analyzed by the Fisher exact test. C, CX3CR1 score in responders (CR/PR) and nonresponders (SD/PD) who were or were not on steroids at baseline. The non-steroid group was separated into anti–PD-1 therapy (black line) and chemo-immunotherapy (red line). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Year:

2025

Corticosteroids are frequently prescribed to patients with non–small cell lung cancer (NSCLC) for palliation of cancer-related symptoms; however, the potential impact of baseline steroid use on immune checkpoint inhibitor (ICI) therapy and its underlying mechanisms remain unclear. In this study, we evaluated clinical outcomes of 277 patients with NSCLC treated with ICI therapy at two academic institutions. Twenty-one patients (8%) were taking steroids at the start of ICIs. Patients on baseline steroids had a lower overall response rate with markedly shorter progression-free survival and overall survival compared with those not receiving steroids. In multivariate analysis, steroid use was the only significant independent risk factor for disease progression and mortality in both independent cohorts, Roswell Park Comprehensive Cancer Center ( n = 88) and University of Southern California ( n = 189). A baseline peripheral blood neutrophil-to-lymphocyte ratio + CD8 + T cells was substantially lower in patients on steroids. Using a bedside-to-bench approach, we found that concurrent steroid use significantly decreased antitumor efficacy of anti–PD-1 therapy and attenuated the increase of CX3CR1 + CD8 + T cells in mice bearing MC38 tumors whereas discontinuation of steroid at the start of treatment did not make a negative impact on survival. Collectively, baseline steroid use was associated with worse outcomes and decreased frequency of circulating differentiated effector T cells in patients with NSCLC. Caution should be taken when interpreting the results from circulating immune-related biomarkers in patients on steroids. Significance: The impact of corticosteroids, widely prescribed for palliation of cancer-related symptoms, on ICI therapy remains unclear. This study shows that baseline steroid use is a negative independent prognostic factor in patients with NSCLC undergoing ICI therapy and provides insights into the decreased T-cell effector differentiation and utility of predictive blood-based markers by steroids.

Year:

2025

The impact of baseline steroid use on predictive and prognostic values of NLR in patients with NSCLC treated with ICI therapy. A–H, ORR, PFS, and OS of patients at RPCCC and USC treated with ICI therapy according to PB-high (≥5) or-low ( A , B , E , and F ) was analyzed by the Fisher exact test. P values for PFF and OS ( C , D , G , and H ) were calculated by a log-rank (Mantel–Cox) test. mOS, median OS; mPFS, median PFS.

Year:

2025

The use of corticosteroids at the initiation of ICI therapy correlates with decreased ORR and worse prognosis in patients with NSCLC. A–D, ORR, PFS, and OS of patients at RPCCC ( A and C ) and USC ( B and D ) treated with ICI therapy on the basis of baseline steroid use. The ORR was analyzed by the Fisher exact test. P values for PFF and OS were calculated by a log-rank (Mantel–Cox) test. mOS, median OS; mPFS, median PFS.

Year:

2025

Continued use of corticosteroids during anti–PD-L1 therapy correlates with decreased survival in a preclinical model. A, Experimental set-up. Mice bearing MC38 tumors were treated with anti–PD-L1 or isotype antibody. Mice were administered with dexamethasone or PBS intraperitoneally before (day −12 to 0) and/or during (day 0–14) anti–PD-L1 therapy. B, Tumor growth curves (mean) and survival curves in MC38 tumor-bearing mice in different treatment groups as indicated. n = 5 to 6 mice. **, P P values were determined by a log-rank (Mantel–Cox) test. C, Frequency of the CX3CR1 + subset in PB CD8 + T cells. PB was collected on day 14. n = 5 to 6 mice. P values were determined by the Kruskal–Wallis test with Dunn multiple comparisons. Data are presented as mean ± SEM. Ab, antibody; dex, dexamethasone; i.p., intraperitoneal; NS, not significant; αPD-L1, anti–PD-L1.

Year:

2025

Intra-organism biodiversity is thought to arise from epigenetic modification of constituent genes and post-translational modifications of translated proteins. Here, we show that post-transcriptional modifications, like RNA editing, may also contribute. RNA editing enzymes APOBEC3A and APOBEC3G catalyze the deamination of cytosine to uracil. RNAsee (RNA site editing evaluation) is a computational tool developed to predict the cytosines edited by these enzymes. We find that 4.5% of non-synonymous DNA single nucleotide polymorphisms that result in cytosine to uracil changes in RNA are probable sites for APOBEC3A/G RNA editing; the variant proteins created by such polymorphisms may also result from transient RNA editing. These polymorphisms are associated with over 20% of Medical Subject Headings across ten categories of disease, including nutritional and metabolic, neoplastic, cardiovascular, and nervous system diseases. Because RNA editing is transient and not organism-wide, future work is necessary to confirm the extent and effects of such editing in humans.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Fumito Ito

Professor

University of Southern California

UNITED STATES
View details

Jorge Nieva

Professor of Clinical Medicine

University of Southern California

UNITED STATES
View details

Ming Li

Professor

University of Southern California

UNITED STATES
View details

Mark Long

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Ryutaro Kajihara

Kumamoto University

JAPAN
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

Hisashi Kanemaru

Kumamoto University

JAPAN
View details

Angelina Lim

University of Southern California

UNITED STATES
View details

Peter Elkin

Professor and Chair

University at Albany, State University of New York

UNITED STATES
View details

Junko Matsuzaki

Research Professor

University of Chicago

UNITED STATES
View details

Zackary Falls

Assistant Professor

University at Buffalo - Downtown Campus

UNITED STATES
View details